Dexcom (NSDQ:DXCM) this week was ordered to pay attorney’s fees in a spat with rival AgaMatrix over patents related to continuous glucose monitoring technology. The ruling came alongside a final judgement of non-infringement in favor of AgaMatrix from Judge S. James Otero of the US District Court for the Central District of California Western Division, according […]
DexCom Inc.
Beta Bionics wins FDA nod for home-use trial of artificial pancreas tech
Beta Bionics said this week that it won FDA approval to start recruiting patients with Type I diabetes for home-use studies of its iLet bionic pancreas system. The trial is slated to test Novo Nordisk’s fast-acting insulin, Fiasp, with the company’s autonomous infusion pump in adults with Type I diabetes. The study will also evaluate […]
Fitbit unveils array of new apps from health partners
Fitbit (NYSE:FIT) revealed today a suite of new apps and clock faces designed to help people manage their health, including a glucose monitoring app from Dexcom (NSDQ:DXCM) that is slated to launch in the second half of 2018. The Las Vegas-based company also announced programming from Diplomat Pharmacy, Humana (NYSE:HUM), One Drop and Walgreens. “Smartwatches provide a […]
Dexcom sales climb 30% in Q1, beating estimates on The Street
Dexcom (NSDQ:DXCM) beat expectations on Wall Street yesterday with its first-quarter results, topping analysts’ sales estimates by $12.3 million. The San Diego, Calif.-based company posted a net loss of -$24.2 million, or -28¢, on sales of $184.4 million for the three months ended March 31, for bottom-line growth of 42% on sales growth of 30% compared […]
Tandem wins CE Mark for t:slim X2 insulin pump
Tandem Diabetes Care (NSDQ:TNDM) said today that its t:slim X2 insulin pump won CE Mark clearance in the European Union. The San Diego, Calif.-based company plans to start selling the device in international markets in the second half of 2018. Tandem’s latest drug-pump won FDA approval in August last year. The t:slim X2 insulin pump features […]
Dexcom CEO on ‘treading new ground’ with G6 glucose monitor
Kevin Sayer sold his first glucose sensor in 1994. More than twenty years later, the chief executive of Dexcom (NSDQ:DXCM) still believes that glucose-monitoring technology can transform the way patients manage their diabetes. This week, Dexcom won FDA approval for its latest continuous glucose monitor. The G6 system is the first of the company’s that does […]
Dexcom wins FDA nod for first interoperable continuous glucose monitor
Dexcom (NSDQ:DXCM) shares jumped yesterday after the company scored a unique FDA approval for its G6 continuous glucose monitor, marking the first time the U.S. regulatory agency has cleared a CGM as “fully interoperable” with other medical devices. The company’s latest CGM also eliminates the need for patients to calibrate the device by pricking their fingers. […]
Meet the insulin-makers and device companies developing smart insulin pens
The global market for connected insulin pens could be worth up to $123 million by 2023, according to a report published this year by Research & Markets. Insulin pens, designed for people who control their diabetes with multiple daily injections instead of a pump or wearable patch, are portable devices that were first introduced in 1985 with […]
Patent board upholds AgaMatrix’s CGM patents in Dexcom IP spat
The legal back and forth between Dexcom (NSDQ:DXCM) and AgaMatrix over the companies’ continuous glucose monitoring IP dates back to March of 2016, when AgaMatrix launched a patent infringement lawsuit against the San Diego, Calif.-based manufacturer in the U.S. District Court of Oregon. Later that year, Dexcom filed for inter parters review with the Patent Trial […]
Dexcom beats The Street with Q4 sales, earnings
Dexcom (NSDQ:DXCM) beat expectations on Wall Street with its fourth quarter and full year financial results, growing its quarterly revenue 29% compared to the same period last year. The San Diego, Calif.-based company posted a net loss of -$9.4 million, or -11¢ per share, on sales of $221 million for the 3 months ended Dec. 31. […]